Knight Therapeutics (TSE:GUD) Stock Price Up 1.6% – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD)’s share price shot up 1.6% during mid-day trading on Tuesday . The stock traded as high as C$6.31 and last traded at C$6.27. 181,254 shares traded hands during mid-day trading, an increase of 180% from the average session volume of 64,832 shares. The stock had previously closed at C$6.17.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$6.50 price target on Knight Therapeutics and gave the stock a “buy” rating in a report on Friday, May 9th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Strong Buy” and a consensus price target of C$7.15.

Knight Therapeutics Stock Up 1.6%

The firm has a fifty day simple moving average of C$5.99 and a 200-day simple moving average of C$5.86. The company has a market capitalization of C$634.21 million, a P/E ratio of -20.93, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.